{"title":"Obesity and hypertension in children and adolescents.","authors":"Soo In Jeong, Sung Hye Kim","doi":"10.1186/s40885-024-00278-5","DOIUrl":null,"url":null,"abstract":"<p><p>As childhood obesity rates increase worldwide, the prevalence of obesity-related hypertension is also on the rise. Obesity has been identified as a significant risk factor for hypertension in this age group. National Health Surveys and meta-analyses show increasing trends in obesity and pediatric hypertension in obese children. The diagnosis of hypertension in children involves percentiles relative to age, sex, and height, unlike in adults, where absolute values are considered. Elevated blood pressure (BP) in childhood is consistently associated with cardiovascular disease in adulthood, emphasizing the need for early detection and intervention. The pathogenesis of hypertension in obesity involves multiple factors, including increased sympathetic nervous system activity, activation of the renin-angiotensin-aldosterone system (RAAS), and renal compression due to fat accumulation. Obesity disrupts normal RAAS suppression and contributes to impaired pressure natriuresis and sodium retention, which are critical factors in the development of hypertension. Risk factors for hypertension in obesity include degree, duration, and distribution of obesity, patient age, hormonal changes during puberty, high-sodium diet, sedentary lifestyle, and socioeconomic status. Treatment involves lifestyle changes, with weight loss being crucial to lowering BP. Medications such as angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers may be considered first, and surgical approaches may be an option for severe obesity, requiring tailored antihypertensive medications that consider individual pathophysiology to avoid exacerbating insulin resistance and dyslipidemia.</p>","PeriodicalId":10480,"journal":{"name":"Clinical Hypertension","volume":"30 1","pages":"23"},"PeriodicalIF":2.6000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11366140/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Hypertension","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s40885-024-00278-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0
Abstract
As childhood obesity rates increase worldwide, the prevalence of obesity-related hypertension is also on the rise. Obesity has been identified as a significant risk factor for hypertension in this age group. National Health Surveys and meta-analyses show increasing trends in obesity and pediatric hypertension in obese children. The diagnosis of hypertension in children involves percentiles relative to age, sex, and height, unlike in adults, where absolute values are considered. Elevated blood pressure (BP) in childhood is consistently associated with cardiovascular disease in adulthood, emphasizing the need for early detection and intervention. The pathogenesis of hypertension in obesity involves multiple factors, including increased sympathetic nervous system activity, activation of the renin-angiotensin-aldosterone system (RAAS), and renal compression due to fat accumulation. Obesity disrupts normal RAAS suppression and contributes to impaired pressure natriuresis and sodium retention, which are critical factors in the development of hypertension. Risk factors for hypertension in obesity include degree, duration, and distribution of obesity, patient age, hormonal changes during puberty, high-sodium diet, sedentary lifestyle, and socioeconomic status. Treatment involves lifestyle changes, with weight loss being crucial to lowering BP. Medications such as angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers may be considered first, and surgical approaches may be an option for severe obesity, requiring tailored antihypertensive medications that consider individual pathophysiology to avoid exacerbating insulin resistance and dyslipidemia.
随着全球儿童肥胖率的增加,与肥胖相关的高血压发病率也在上升。肥胖已被确定为这一年龄组患高血压的重要风险因素。全国健康调查和荟萃分析表明,肥胖儿童和肥胖儿童小儿高血压呈上升趋势。儿童高血压的诊断涉及相对于年龄、性别和身高的百分位数,这与成人不同,成人考虑的是绝对值。儿童时期的血压(BP)升高一直与成年后的心血管疾病有关,这就强调了早期发现和干预的必要性。肥胖症高血压的发病机制涉及多个因素,包括交感神经系统活动增加、肾素-血管紧张素-醛固酮系统(RAAS)激活以及脂肪堆积导致的肾脏压缩。肥胖会破坏 RAAS 的正常抑制作用,并导致压力纳尿和钠潴留功能受损,这是高血压发病的关键因素。肥胖症导致高血压的风险因素包括肥胖程度、持续时间和分布、患者年龄、青春期荷尔蒙变化、高钠饮食、久坐不动的生活方式和社会经济地位。治疗包括改变生活方式,其中减轻体重是降低血压的关键。可首先考虑使用血管紧张素转换酶抑制剂或血管紧张素 II 受体阻滞剂等药物,严重肥胖者可选择外科手术治疗,同时需要考虑个体病理生理学因素,量身定制降压药物,以避免加重胰岛素抵抗和血脂异常。